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An enhanced expression of transforming growth factor-a (TGF~) was demonstrated in two clones of NOG-8 mouse 
mammary epithelial ceils, NOG-8 SR1 and NOG-8 SR2, that have been transformed by a v-Ha-ras oneogene. The 
amount of TGF~t production in NOG-8 SRI and NOG-8 SR2 ceils was dependent on the level of p21 r'~ expression i
these clones, which directly correlated with their cloning efficiency insoft agar. There was also a decrease in the number 
of epidermal growth factor (EGF) receptors on the NOG-8 SR1 and NOG-8 SR2 ceils that is proportional to the amount 
of TGFct secreted. These ffects were specific for ras because neu-transformed NOG-8 ceils grew in soft agar at a compara- 
ble level to NOG-8 SR2 ceils yet did not show any increase in TGF~ production or change in EGF receptor expression. 
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1. INTRODUCTION 
Transforming growth factor-a (TGFa)  is a 
growth factor that is a mitogenic peptide and that 
is structurally and functionally related to epidermal 
growth factor (EGF) [1]. In this respect, TGFcr 
binds to the EGF receptor (c-erbB) and activates 
the EGF receptor tyrosine kinase [1,2]. Elevated 
levels of  TGFcr have been found in a number of  ro- 
dent and human breast carcinomas [3-6]. TGFa  
expression can be enhanced by estrogens in 
estrogen-responsive rat and human breast tumor 
cell lines [4-6]. In addition, we have demonstrated 
previously that transformation of  two different 
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mouse mammary  epithelial cell lines with an ac- 
tivated c-Ha-ras proto-oncogene induces an in- 
crease in both TGFcr mRNA expression and TGF~ 
protein production [7,8]. In fact, the increase in 
TGF~ synthesis in ras-transformed NOG-8 mouse 
mammary  epithelial cells is coordinately and tem- 
porally coupled to a change in ras gene expression 
[8]. These results collectively suggest that TGFa  
may be functioning as an autocrine growth factor 
for breast cancer cells and that TGFcr may be ac- 
ting as an intermediary in the transformation path- 
way for an activated ras proto-oncogene in mam- 
mary epithelial cells [9,10]. 
The present study was undertaken to determine 
if there is a gene-dosage effect of  p21 ras expression 
on TGFcr production in two different clones of  v- 
Ha-ras-transformed NOG-8 mouse mammary  epi- 
thelial cells and to ascertain if this effect was 
specific for ras-transformed mouse mammary  cells 
or if it can be detected in NOG-8 cells that have 
been transformed by an entirely different activated 
proto-oncogene such as neu (erbB-2). The neu gene 
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was selected because the p185 neu prote in  is 
homologous  to the EGF  receptor  and because there 
is a substant ia l  body  o f  cl inical  ev idence 
demonst ra t ing  that  ampl i f i ca t ion  and/or  overex-  
press ion  o f  this p ro to -oncogene is assoc iated with a 
subset  o f  more  aggressive pr imary  human breast 
tumors  [11-13]. 
brane (ICN Biomedicals, Costa Mesa, CA) [18] and hybridized 
sequentially as previously described [8] to the following 32p_ 
labeled, nick-translated eDNA probes: a 6.6-kb BamHI frag- 
ment of a human c-Ha-ras eDNA probe [19]; a 406-bp EcoRI- 
ApaI restriction fragment derived from a human TGFa eDNA 
clone, pTGF-CI [20]; a 6.0-kb EcoRI/HindlII fragment of the 
human c-myc eDNA probe [21]; and a 770-bp human ~-actin 
eDNA probe (Oncor, Gaithersburg, MD). 
2. MATERIALS  AND METHODS 
NOG-8 cells are an epithelial subclone of a nontumorigenic 
mouse mammary cell line, NMuMg, originally isolated from the 
mammary gland of NaMru mice [14]. NOG-8 SRI and NOG-8 
SR2 cells are two different clones of NOG-8 cells that were 
derived after infection with the recombinant retroviral pZSR 
vector containing the murine Harvey sarcoma virus v-Ha-ras 
oncogene and the neomycin resistance gene and after selection 
for G418 resistance, as previously described [15]. NOG-8 neu 
cells are a G418-resistant population of NOG-8 cells that had 
been cotransfected after calcium phosphate precipitation with 
an expression vector plasmid containing the point-mutated rat 
neu proto-oncogene linked to the SV40 early promoter and the 
pSV2neo plasmid [14]. The cells were grown in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10070 
fetal bovine serum (FBS), 100 U/ml penicillin, 100/~g/ml strep- 
tomycin (GIBCO, Grand Island, NY) in a 5070 CO2 humidified 
incubator at 37°C. 
For soft agar growth, 2 x 104 cells/35-mm dish were seeded 
into 0.3070 Difco Noble agar (Difco, Detroit, MI) supplemented 
with DMEM containing 1007o FBS, layered over a base layer of 
0.807o agar medium. After 12 days, cells were stained with nitro 
blue tetrazolium (Sigma Co., St. Louis, MO), and colonies 
larger than 50,um were counted with an Artek 880 colony 
counter (Artek System, Farmingdale, NY). 
Preparation of conditioned medium (CM) that was collected 
over a 48-h period from cultured ceils and determination of
TGF~ protein by radioimmunoassay (RIA) and by radiorecep- 
tor assay (RRA) were performed as previously described [5,8]. 
Western blot analysis of the p21 ras i~rotein was performed us- 
ing the rat monoclonal anti-p21 '~s antibody, Y13-259, as 
previously described [16]. 
Western blot analysis of the p185 ~e~ protein was carried out 
using 21 N, a rabbit polyclonal anti-neu anti-serum that was rais- 
ed against a synthetic peptide corresponding to the C-terminal 
region of the human c-erbB-2 protein (residues 1243-1255) as 
previously described [17]. 
The specific binding of ]25I-EGF was performed on cells in 
monolayer culture using mouse ~25I-EGF (spec. act. 100/zCi//~g, 
Amersham, Arlington Heights, IL) as previously described [7]. 
The number of EGF-binding sites and the Ads for binding were 
determined by Scatchard analysis of the specific-binding 
isotherms [8]. 
Poly(A) ÷ RNA was isolated from the cells, and equivalent 
amounts (10/~g/lane) were electrophoresed through a de- 
naturating 1.2% agarose/2.2 M formaldehyde g l [5]. Ethidium 
bromide staining of the gels before blotting demonstrated that 
each lane contained equivalent amounts of RNA. The RNA was 
then transferred by capillary blotting to a Biotrans nylon mem- 
3. RESULTS AND DISCUSSION 
In fec t ion  o f  p r imary  mouse  mammary  epithel ia l  
cells or  establ ished NOG-8  mouse  mammary  epi- 
thel ia l  cells with the recombinant  pZSR virus con-  
ta in ing the viral  Ha- ras  oncogene results in the 
anchorage- independent  g rowth  o f  these cells in soft  
agar  and  their  abi l i ty to fo rm und i f fe rent ia ted  car- 
c inomas  in nude mice [15]. Several  independent  
c lones o f  v-Ha- ras - in fec ted  NOG-8  cells were 
iso lated and expanded af ter  G418 select ion.  A l -  
though un in fected  NOG-8  cells fai led to grow in 
soft  agar,  two o f  these v-Ha- ras - in fec ted  clones,  
NOG-8  SR1 and NOG-8  SR2, exhib i ted soft  agar  
co lony  fo rming  eff ic iencies ranging f rom approx-  
imate ly  7 .5% for  NOG-8  SR1 cells to 15% for  
NOG-8  SR2 cells (fig. 1A). NOG-8  cells t ransfected 
with an act ivated rat c-neu gene also grew ag- 
gressively in soft  agar  and exhib i ted a c lon ing eff i -  
c iency that  was comparab le  to the v-Ha- ras -  
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Fig. 1. (A) Anchorage-independent growth in soft agar of v-Ha- 
ras- and neu-transformed NOG-8 cell lines. Data represent an 
average (+ SD) of four experiments in quadruplicate. (B) 
Western blotting of p21 '~S levels in v-Ha-ras- and neu- 
transformed NOG-8 cell lines. 
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transformed NOG-8 SR2 cells. After injection of 
1 × 106 cells in the dorsal flank of 4- to 6-week-old 
nude mice, NOG-8 SR1 cells formed tumors in 
100% of the animals within 6-7 weeks whereas 
NOG-8 SR2 cells formed tumors in all of the mice 
after only 2 weeks [151. The neu- t rans fected  
NOG-8 cells formed histologically comparable 
tumors as v-Ha- ras - t rans formed NOG-8 cells. In- 
jection of a comparable number of NOG-8 neu 
cells led to the development of tumors in two of 
two nude mice within 3-4 weeks. 
The relative levels of total endogenous c -Ha- ras  
and v-Ha- ras  protein in these cells was determined 
by Western blot analysis and subsequent den- 
sitometric scanning. As shown in fig.lB, NOG-8 
SR1 cells expressed approximately 6-8-fold more 
p21 "a~ protein than the uninfected, parental NOG-8 
cells, which expressed low levels of endogenous 
p21 "a~. NOG-8 SR2 cells exhibited approximately 
30-fold more p21 "~ than the NOG-8 cells, whereas 
little or no p21 '~ was detected in the NOG-8 neu 
cells. NOG-8 neu cells produced elevated amounts 
of p 185 neu as determined by Western analysis (data 
t r  
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Fig.2. Northern blot analysis of v-Ha-ras inRNA (A), TGFo~ 
mRNA (B), fl-actin mRNA (C) and c-myc mRNA (D) in v-Ha- 
ras- and neu-transformed NOG-8 cell lines. 
not shown). In contrast, no p185 "e" was found in 
the NOG-8 cells. Northern blot analysis 
demonstrated the presence of a 4.8-kb pZSR viral 
transcript in the NOG-8 SR1 and NOG-8 SR2 cells 
but not in the uninfected NOG-8 or NOG-8 neu 
cells (fig.2A). In fact, the relative level of expres- 
sion of this transcript correlated reasonably well 
with the amount of p21 ras protein that was present 
in these two v-Ha- ras - t rans formed NOG-8 clones. 
Enhanced production and secretion of TGFoe are 
frequently associated with rodent fibroblasts and 
epithelial cells that have been transformed with an 
activated c -Ha- ras  proto-oncogene and v-K i - ras  or 
v-Ha- ras  oncogenes [7,8,22,23]. To ascertain if 
there was any relationship among the level of v-Ha- 
ras expression, soft agar growth and TGFa pro- 
duction, CM from these cell lines was analyzed for 
immunoreactive and biologically active TGFot in a 
RIA and RRA, respectively. As shown in fig.3, the 
levels of biologically active and immunoreactive 
TGFce were equivalent within each of the cell lines. 
NOG-8 cells secreted low levels of TGFa 
(5-10 ng/10 s cells/48 h), whereas NOG-8 SR1 
cells produced 4-5-fold (35-40 ng/10 s cells/48 h) 
and NOG-8 SR2 cells produced 8-10-fold 
(80-90 ng/10 s cells/48 h) higher levels of TGFa 
than NOG-8 cells. In contrast, NOG-8 neu cells did 
not show any change in TGFa production com- 
pared with NOG-8 cells. These differences in 
secreted TGFoe are reflected by comparable 
z co ~ (9 
o o o 
z z z 
Fig.3. Immunoreactive (O) and biologically active (m) TGFoe 
protein levels in the CM obtained from v-Ha-ras- and neu- 
transformed cell lines. Data represent an average (± SD) of 
three experiments in duplicate. 
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changes in the amount of a 4.8-kb TGFa~-specific 
mRNA transcript that can be detected in these cell 
lines (fig.2B). In fact, the differences in TGF~ 
mRNA expression that are observed in the in- 
dividual NOG-8 cell lines are not due to variations 
in the amount of RNA that is loaded on the gels 
because all the cells expressed a comparable vel of 
~-actin mRNA (fib.2C). In addition, the change in 
TGF~ mRNA expression that is observed after ras 
transformation is specific for this growth factor 
because the levels of c -myc  mRNA were approx- 
imately equivalent (fig.2D). 
One consequence of an increase in TGFt~ pro- 
duction and secretion in a number of different ras- 
transformed cells is a reduction in the number of 
EGF receptors that can be measured on the surface 
of these cells [7,8,24]. This phenomenon is prob- 
ably due in large part to a chronic occupation of 
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Fig.4. ]25I-EGF specific binding to NOG-8 cells (~---~), 
NOG-8 SR1 cells (B---B), NOG-8 SR2 cells (0-----<3) and 
NOG-8 neu cells (~) .  (Inset) Scatchard plots of the binding 
isotherms. Data represent an average of three experiments in 
duplicate. The SD was less than 10%. 
these receptors by endogenously produced TGFa~, 
which results in a down-regulation of these recep- 
tors [1,7,8,22]. Fig.4 demonstrates the specific 
binding of different concentrations of 125I-EGF to 
the v-Ha- ras - t rans formed NOG-8 SR1 and SR2 
clones and to NOG-8 neu- t rans formed cells. 
Saturation of specific binding in all the cell lines oc- 
curred between 10 and 25 ng/ml of z25I-EGF. 
NOG-8 cells and transformed NOG-8 neu cells 
bound approximately equal amounts of IESI-EGF 
and possessed between 90000 and 95000 EGF 
receptor sites/cell as determined by Scatchard 
analysis (fig.4, inset). In contrast, NOG-8 SR2 cells 
showed a 90% reduction in the number of EGF 
receptor sites ( -12000 sites/cell) while NOG-8 
SR1 cells exhibited almost a 50% reduction in EGF 
receptor sites (47000 sites/cell) compared with 
NOG-8 cells. All of the cell lines except he NOG-8 
SR2 cells showed at least two classes of EGF recep- 
tor sites with a high affinity of 2.5 × 10 -~° M and 
a low affinity of 1 x 10 -9 M. NOG-8 SR2 cells 
lacked the high-affinity class of receptor sites, 
which is in agreement with previous tudies show- 
ing that high levels of ras expression or TGFtx pro- 
duction have to be reached before there is a loss in 
the high-affinity population of EGF receptors 
[8,251. 
The results of this study demonstrate that the 
amount of TGFa produced in Ha-ras - t rans formed 
mammary epithelial cells is dependent on the levels 
of p21 ras expression in these cells. This may have 
some clinical significance because an enhanced ex- 
pression of p21 c-na-ras and c-Ha-ras mRNA has 
been detected in a majority of primary human 
breast tumors [26,27]. Furthermore, the levels of 
secreted TGFot can be correlated reasonably well 
with the cloning efficiency of these cells in soft 
agar, which is an accurate in vitro index of their 
tumorigenicity. Specifically, NOG-8 SR2 cells ex- 
pressed approximately 3-4-fold more p21 ~as than 
NOG-8 SR1 cells and exhibited twice the soft agar 
colony forming ability as NOG-8 SR1 cells. These 
differences are reflected by a 2-fold higher level of 
TGF~ production in the NOG-8 SR2 cells com- 
pared with the NOG-8 SRI cells. These results sup- 
port a role for TGF~ in the transformation of 
mammary epithelial cells that can be produced by 
an activated ras gene and further suggest that 
TGFa~ production is strongly coupled to a regula- 
tion of ras gene expression. In addition, this effect 
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is apparently specific for ras because neu-trans- 
formed NOG-8 mammary  epithelial cells failed to 
show any change in TGFtr production, although 
they are equally as efficient as ras- t ransformed 
NOG-8 cells for cloning in soft agar and for form- 
ing tumors in nude mice. This suggests that neu 
may funct ion through a different t ransformat ion 
pathway than ras, at least with respect to the poten- 
tial involvement of TGFo~. 
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